The work, published in Molecular Cancer, addresses a long-standing frustration in tumor biology. Cancer-associated fibroblasts, or CAFs, have been recognized for decades as central players in stromal remodeling, immune exclusion, and drug resistance, but most classifications of these cells have been static snapshots. Pathologists and single-cell biologists could label fibroblasts as myofibroblastic, inflammatory, or antigen-presenting subtypes, yet the field lacked a causal account of how tumor cells instruct fibroblasts to adopt these pathogenic identities in the first place. The new study set out to answer precisely that question: does the tumor merely coexist with certain fibroblast states, or does it actively manufacture them?

To map the landscape, the team performed integrative single-cell RNA sequencing on lung adenocarcinoma specimens, constructing a detailed stromal atlas of the disease and tracing fibroblast lineage trajectories. Rather than falling into discrete categories, fibroblasts in these tumors followed a continuous differentiation path that converged on a myofibroblast-like endpoint marked by MMP11 expression. This MMP11-positive subset carried a transcriptional program dominated by extracellular matrix remodeling and collagen organization, and its gene-expression signature overlapped strongly with markers of immune exclusion. Across multiple independent patient cohorts, the abundance of this fibroblast state tracked with worse clinical outcomes, suggesting it is not a bystander but an active participant in disease progression.

The next question was mechanistic: what turns ordinary fibroblasts into MMP11-producing matrix builders? The researchers co-cultured tumor cells with fibroblasts and found that different lung adenocarcinoma cell lines varied dramatically in their ability to trigger the program. When they separated the tumor cells’ influence into soluble factors and extracellular vesicles, the vesicle fraction carried most of the programming activity. Extracellular vesicles are nanoscale lipid-enclosed particles that cells release to shuttle proteins, lipids, and nucleic acids to recipient cells, functioning as a kind of biological postal system. Using isolation and functional fractionation techniques, the team demonstrated that removing vesicles from tumor-conditioned media largely abolished the induction of the MMP11-positive state, while purified vesicles restored it.

To identify the cargo responsible, the researchers turned to quantitative proteomics of the vesicles themselves, comparing vesicles with high CAF-programming activity against those with low activity using both data-dependent and data-independent acquisition mass spectrometry. One protein stood out: secreted phosphoprotein 1, better known as SPP1 or osteopontin, a secreted glycoprotein previously implicated in metastasis and immune regulation. SPP1 was selectively enriched in the vesicles that most potently drove fibroblast reprogramming, indicating that the tumor does not simply dump a generic mix of molecules into its vesicles but actively sorts specific signaling proteins into them.

The mechanistic chain was then traced to its receptor. Vesicle-associated SPP1, the study found, engages primarily the CD44 receptor on the surface of fibroblasts. This binding activates the PI3K-AKT signaling pathway, a canonical pro-survival and pro-growth cascade, and sustains the transcriptional changes that push fibroblasts into the MMP11-positive phenotype. Genetic and pharmacologic perturbations confirmed the pathway’s causality: blocking SPP1, CD44, or PI3K-AKT signaling prevented the fibroblast reprogramming in co-culture systems. In other words, the tumor-to-stroma communication is not diffuse background noise but a specific, druggable ligand-receptor axis.

The clinical implications emerged clearly from multiplex immunofluorescence staining of lung adenocarcinoma specimens. Tumors rich in MMP11-positive fibroblasts showed dense collagenous matrix deposition, physical exclusion of T cells from the tumor nests, and reduced intratumoral immune infiltration. In cohorts of patients treated with chemo-immunotherapy, the presence of this fibroblast state predicted poorer responses, consistent with the idea that a matrix-rich, immune-excluded microenvironment undermines the ability of checkpoint inhibitors to mobilize anti-tumor T cells. The findings thus provide a mechanistic bridge between a specific stromal cell state and the well-known clinical problem of immunotherapy resistance in lung cancer.

Crucially, the study went beyond correlation and tested whether interrupting the EV-SPP1 axis could reverse the process in living organisms. In immunocompetent mouse models of lung tumor growth and metastasis, disrupting the pathway reduced the development of MMP11-positive CAFs, loosened the dense stromal architecture, and revived anti-tumor T-cell immunity. Most strikingly, combining EV-SPP1 pathway disruption with PD-1 immune checkpoint blockade made tumors substantially more sensitive to the immunotherapy, transforming a resistant microenvironment into one that immune cells could penetrate and attack. This positions the vesicle cargo protein not just as a biomarker but as a candidate therapeutic target in its own right.

The broader significance of the work lies in reframing how scientists think about the tumor microenvironment. Rather than treating fibroblast diversity as an intrinsic property of stromal cells, the study shows that tumor cells can actively author the identity of their neighbors through targeted vesicle-mediated delivery of signaling proteins. This tumor-instructed model of stromal reprogramming suggests that effective immunotherapy strategies in lung adenocarcinoma may need to target the communication lines between cancer cells and fibroblasts, not only the immune checkpoints themselves. If the EV-SPP1-CD44-PI3K-AKT circuit can be safely intercepted in patients, it could convert a large fraction of immune-excluded, therapy-resistant lung tumors into ones that respond to existing treatments, offering a rational path to combination regimens built on the biology of intercellular vesicle trafficking.

Subject of Research: Tumor-derived extracellular vesicle SPP1 programming of MMP11-positive cancer-associated fibroblasts driving immune exclusion in lung adenocarcinoma

Article Title: Extracellular vesicle–enriched SPP1 programs MMP11⁺ fibroblast states to drive immune exclusion in lung adenocarcinoma

Article References: He, X., Qian, L., Zhao, D., Wang, G., Zhang, X., Ye, Y., Li, L., Wen, Y., & Zhang, L. (2026). Extracellular vesicle–enriched SPP1 programs MMP11⁺ fibroblast states to drive immune exclusion in lung adenocarcinoma. Molecular Cancer. https://doi.org/10.1186/s12943-026-02785-5

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02785-5

Keywords: lung adenocarcinoma, cancer-associated fibroblasts, extracellular vesicles, SPP1, MMP11, immune exclusion, tumor microenvironment, immunotherapy resistance, PD-1 blockade, PI3K-AKT signaling, CD44, single-cell RNA sequencing

Emerging research has illuminated the role of tumor-derived EVPs in the establishment of pre-metastatic niches (PMNs) within distant organs. This process involves the selective priming of remote tissues, effectively conditioning them to support the colonization and outgrowth of metastatic cancer cells. EVPs deliver a cargo comprised of proteins, lipids, and nucleic acids that remodel the extracellular matrix, modulate local immune cell populations, and influence stromal cell behavior. Through these multifaceted mechanisms, EVPs not only facilitate metastatic dissemination but also engender significant immune dysregulation within PMNs, undermining the organ-specific defenses that would ordinarily impede tumor cell invasion.

Moreover, cancer-associated EVPs are implicated in systemic complications that extend into the realms of thrombosis and cardiovascular disease. The pro-coagulant nature of certain EVP populations contributes to the heightened risk of thrombotic events observed in cancer patients, a leading cause of morbidity and mortality. These vesicles modulate endothelial function, platelet aggregation, and coagulation cascades, creating a prothrombotic milieu. Concurrent cardiovascular impairment further exemplifies the broad-reaching consequences of EVP-mediated intercellular communication, linking tumor biology with systemic vascular pathology in an intricate interplay that exacerbates patient outcomes.

Beyond the vascular system, tumor-secreted EVPs exert profound effects on hepatic metabolism. The liver, a central hub for metabolic regulation, becomes a target for EVP-induced reprogramming that disrupts lipid and glucose processing. This hepatic dysfunction manifests as metabolic derangements with systemic repercussions, including insulin resistance and altered energy homeostasis. These pathophysiological changes underpin various cancer-associated metabolic syndromes, highlighting the liver’s vulnerability to EVP-driven remodeling and underscoring the systemic nature of oncogenic signaling facilitated by these vesicles.

In parallel, the influence of cancer-associated EVPs extends to glucose metabolism disorders, compounding the metabolic dysregulation stemming from hepatic impairment. Tumor-derived EVPs impact pancreatic beta cell function and systemic insulin sensitivity, promoting hyperglycemia and fostering an environment that supports tumor growth. This bidirectional metabolic crosstalk exemplifies a vicious cycle wherein cancer progression and metabolic disease synergistically exacerbate one another, emphasizing the need for holistic therapeutic interventions that address both oncologic and metabolic derangements.

Cachexia, a debilitating wasting syndrome characterized by severe muscle and adipose tissue loss, is another devastating paraneoplastic consequence propelled by EVP activity. EVPs carry factors that drive systemic inflammation and catabolic signaling pathways, accelerating tissue degradation and impairing anabolism. This multifactorial syndrome impacts quality of life and survival, illustrating the catastrophic systemic reach of EVPs beyond the tumor microenvironment into whole-body homeostasis.

Distinct from these metabolic and inflammatory manifestations are paraneoplastic syndromes targeting the nervous system, wherein EVP-mediated communication perturbs neural function and induces neurological deficits. The transport of neurotoxic or immune-modulating cargo by cancer-secreted vesicles contributes to neural damage, cognitive impairment, and neuropathies, underscoring the neurobiological dimension of EVP-related systemic pathology. This expands the clinical frontiers of cancer’s influence, revealing previously underappreciated mechanisms of neural-endocrine disruption.

The complexity of EVP-mediated systemic effects is further amplified by the dynamic interactions involving host-, diet-, and microbiota-derived EVPs. These various extracellular vesicle populations engage in a sophisticated interplay with tumor cells, influencing cancer progression and therapeutic resistance. Dietary components and microbial communities modulate EVP composition and function, integrating environmental factors into the tumor-host dialogue. This intricate network mediates response variability and opens avenues for microbiota-targeted and nutritional strategies aimed at modulating EVP profiles to improve treatment outcomes.

Therapeutically, EVPs present both challenges and opportunities. Their role as mediators of systemic dysfunction makes them compelling targets for intervention, with prospects ranging from inhibiting deleterious vesicle release to harnessing EVPs as delivery vehicles for anti-cancer agents. Engineering EVPs to carry immunomodulatory or cytotoxic payloads represents a promising frontier in systemic cancer therapy, potentially enabling precision targeting of both tumors and their systemic sequelae. However, the complex biology of EVPs demands nuanced approaches that consider their diverse origins, cargo heterogeneity, and functional versatility.

The recognition of cancer as a systemic disease, orchestrated in part through EVP-mediated inter-organ communication, mandates a paradigm shift in oncologic treatment approaches. Traditional strategies focusing solely on tumor eradication fall short of addressing the multifaceted systemic perturbations driven by EVP signaling. A holistic approach, targeting not only the localized tumor but also its systemic metabolic, immunological, and neurological consequences, offers a more comprehensive model for improving patient prognosis and quality of life.

Future research aims to delineate the precise molecular mechanisms governing EVP biogenesis, cargo selection, and uptake, as well as their specific roles in various organ systems. This knowledge will enhance the development of biomarkers for early detection, prognostication, and the monitoring of systemic disease burden. Implementing EVP profiling in clinical settings could transform personalized medicine by enabling tailored interventions that counteract systemic effects while optimizing anti-tumor efficacy.

The systemic health alterations promoted by EVPs extend beyond mere clinical symptoms; they represent fundamental disruptions in cellular communication networks that maintain organismal equilibrium. Understanding these disruptions at a molecular and cellular level unravels the complexity of cancer pathophysiology and highlights novel therapeutic vulnerabilities. Integrating insights from EVP biology into clinical oncology holds promise for not only extending survival but also mitigating the multifactorial burdens of cancer-associated comorbidities.

In summary, the systemic impact of cancer-associated extracellular vesicles and particles embodies a transformative area of oncology research, unveiling the far-reaching influence of tumors on host physiology. These findings compel a re-evaluation of cancer from a localized disease to a multifaceted systemic disorder, driven by intricate EVP networks that foster metastasis, metabolic derangements, immune escape, and organ dysfunction. Holistic treatment paradigms that address this complexity through the modulation or exploitation of EVPs could revolutionize cancer therapy and improve comprehensive patient care.

As investigations continue, the intersection of EVP biology with immunology, metabolism, neurology, and microbiome science promises to yield integrated strategies that combat the systemic consequences of cancer. Leveraging the dual roles of EVPs—as both disease mediators and therapeutic tools—could unlock novel clinical avenues for managing cancer’s broad assault on human health. This evolving understanding ultimately underscores the necessity to transcend tumor-centric models and embrace systemic frameworks that encompass the full spectrum of cancer’s impact.

In this new era of oncology, where extracellular vesicles and particles emerge as both villains and potential heroes, a more nuanced appreciation of cancer’s systemic nature propels scientific discovery and therapeutic innovation. The future of cancer treatment lies in unraveling these complex vesicular communications that transcend traditional boundaries, paving the way for interventions that restore homeostasis, thwart metastasis, and enhance survival. This holistic vision heralds a paradigm shift, positioning extracellular vesicles and particles at the forefront of systemic cancer biology and clinical therapeutics.

Subject of Research: Systemic effects of cancer-associated extracellular vesicles and particles (EVPs) on host tissues, organ dysfunction, cancer progression, and therapeutic applications.

Article Title: Systemic health impact of cancer-associated extracellular vesicles and particles

Article References:

Wang, G., Lucotti, S., Bojmar, L. et al. Systemic health impact of cancer-associated extracellular vesicles and particles.
Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00952-w

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00952-w

Keywords: extracellular vesicles, cancer, systemic disease, metastasis, pre-metastatic niche, metabolic dysfunction, immune dysregulation, thrombosis, cachexia, paraneoplastic syndromes, tumor microenvironment, microbiota, therapeutic EVPs

Cancer cells have evolved numerous methods for evading the immune response, and the secretion of extracellular vesicles represents one of the most cunning. These vesicles, which can include exosomes and microvesicles, are released into the tumor microenvironment and the systemic circulation, acting as messengers that impact distant and proximate cells alike. Zeng and colleagues highlight how these vesicles carry a cargo rich in proteins, lipids, and genetic material, which play pivotal roles in modifying immune responses and promoting a supportive environment for tumor growth.

One of the critical aspects of tumor-derived extracellular vesicles is their ability to alter the metabolic landscape of immune cells. Zeng et al. provide compelling evidence that these vesicles can induce a shift in the metabolism of T cells and macrophages—key players in anti-tumor immunity. This reprogramming leads to what some researchers have termed an “immunosuppressive phenotype,” which compromises the ability of immune cells to recognize and attack tumor cells effectively. By hijacking these metabolic pathways, tumors can effectively shield themselves from immune surveillance.

Furthermore, another layer of complexity is added by the notion that tumor-derived EVs can influence not just immune cells but also the endothelial cells that line blood vessels in the tumor microenvironment. The study demonstrates that these vesicles can enhance angiogenesis, the process by which new blood vessels form from existing ones. This is crucial for tumors, which depend on a robust vascular supply to thrive and metastasize. The modulation of endothelial cell metabolism by tumor-derived EVs exemplifies the multifaceted nature of the tumor-immune interface.

Another striking finding from Zeng et al. is the connection between extracellular vesicles and the development of resistance to immunotherapy. Cancer immunotherapy, while having revolutionized the treatment landscape for many malignancies, is not universally effective. The presence of tumor-derived EVs has been shown to correlate with poorer outcomes in patients undergoing such therapies, suggesting that these vesicles may contribute to treatment failure. The study reveals that by downregulating immune checkpoint markers and influencing various signaling pathways involved in immune activation, EVs can create an environment resistant to the effects of therapeutic agents.

Zeng and colleagues also introduce new potential therapeutic strategies that could harness this knowledge. Developing specific inhibitors or modifiers of extracellular vesicle function could improve the efficacy of existing immunotherapies. Moreover, the study proposes the idea of engineering EVs to carry therapeutic agents or immune modulators to re-educate T cells and other immune components. The clinical implications of these potential interventions could be profound, paving the way for more successful outcomes in cancer treatment.

Another fascinating angle explored in the study pertains to the hands of the tumor microenvironment—how it not only serves as a battlefield for immune and cancerous cells but also actively reshapes the immune landscape over time. Zeng et al. discuss the temporal dynamics of EV release in relation to tumor progression and treatment responses. This insight could lead to the development of biomarkers that help predict tumor behavior and responsiveness to therapies.

In addition, the researchers underline the need for a deeper understanding of the molecular constituents of tumor-derived EVs. The proteins, lipids, and RNA molecules carried in these vesicles often reflect the state of their parent tumor cells, making them potential biomarkers for diagnosis and prognosis. Zeng et al.’s work encourages a comprehensive analysis of the vesicular cargo to derive better insights into the tumor’s behavior and the immune landscape.

One cannot overlook the implications of this research on the personalized medicine front. The individual variability in EV profiles could inform tailored therapeutic strategies that consider a patient’s unique tumor environment and immune makeup. This could herald a transformative approach in oncology, moving away from a one-size-fits-all regimen to more nuanced, patient-specific therapies that enhance treatment efficacy while reducing adverse effects.

While the study’s findings are exciting, they also unveil a plethora of questions that demand further investigation. The specific mechanisms through which EVs mediate their effects on immune cells vary widely and are still not completely understood. Future research must aim to delineate these pathways, distinguishing between pro- and anti-tumor functions of different populations of EVs under various conditions. This understanding will be critical for designing rational therapeutic interventions.

Understanding the role of EVs in tumor biology also sheds light on the broader implications of cancer treatment in the context of other chronic diseases. As research in immunometabolism burgeons, the parallels between cancer and other conditions such as autoimmune diseases, obesity, and metabolic syndrome could illustrate fundamental biological processes governed by extracellular vesicles. Zeng et al.’s work is a pioneering step in bridging these fields and fostering a cohesive dialogue between cancer researchers and specialists in other areas of medicine.

As this area of research grows, multidisciplinary collaboration will be essential. The interplay of cancer biology, immunology, biochemistry, and clinical medicine highlights the complexity of developing effective treatment strategies. The work of Zeng et al. serves as a call to action for the scientific community to unify efforts, combining expertise from diverse fields to tackle the challenges posed by tumor-derived extracellular vesicles.

In conclusion, the study by Zeng and colleagues culminates in a significant advancement in our understanding of how tumor-derived extracellular vesicles alter immune responses and contribute to therapeutic resistance. By offering insights into these underlying mechanisms, the authors not only pave the way for innovative approaches to combat cancer but also challenge researchers to frame the ongoing narrative of cancer treatment in light of the evolving dynamics of the immune system. The potential for harnessing this knowledge to develop targeted therapies illuminates a hopeful path forward in the fight against cancer.

Subject of Research: Tumor-derived extracellular vesicles and their role in immunometabolic reprogramming and immunotherapeutic resistance.

Article Title: Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.

Article References:

Zeng, H., Zhang, R., Zhu, X. et al. Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.
Mol Cancer (2026). https://doi.org/10.1186/s12943-025-02556-8

Image Credits: AI Generated

DOI: 10.1186/s12943-025-02556-8

Keywords: extracellular vesicles, tumor biology, immunometabolism, immunotherapy resistance, cancer treatment, immune cell reprogramming, therapeutic strategies.

Extracellular vesicles have become a major focus of study because of their pivotal role in intercellular communication, particularly in the progression of cancers. Tumor-derived EVs can travel to distant sites in the body and prepare new environments conducive to cancer growth, a harbinger of metastasis. Until now, however, the precise molecular interactions enabling EVs to latch onto recipient cells and initiate these processes remained unclear. The latest research directly addresses this mystery, utilizing cutting-edge imaging techniques and molecular analyses to delineate the binding mechanisms underlying vesicle-cell interactions.

The study, published in the Journal of Cell Biology on April 30, 2025, zeroes in on small extracellular vesicles (sEVs) derived from multiple tumor cell lines. The research team, led by Professor Kenichi G.N. Suzuki of the Institute for Glyco-core Research and the National Cancer Center Research Institute in Japan, applied super-resolution microscopy and single-molecule imaging to track and characterize these vesicles at an unprecedented level of detail. This approach allowed them to identify the key molecular players responsible for the selective adhesion of sEVs to recipient cellular membranes.

Central to their findings is the identification of integrin heterodimers, which are protein complexes known for mediating cell adhesion and signaling. The research revealed that sEVs express specific integrin heterodimers associated with a tetraspanin protein called CD151. Tetraspanins, though small, are essential for the structural organization and function of EVs, guiding their formation and cargo sorting. The integrins linked to CD151 appear to be instrumental in targeting the vesicles to recipient cells through a particular extracellular matrix protein called laminin.

Laminin, a glycoprotein found abundantly within the extracellular matrix, is critical for maintaining cellular architecture and facilitating adhesion and migration. The study demonstrated that sEVs bind preferentially to laminin, rather than other matrix proteins such as fibronectin, highlighting a specificity in the interaction that goes beyond mere adhesion to extracellular components. This selective binding suggests a refined targeting mechanism through which EVs seek out and interact with recipient cells, possibly influencing where and how metastases develop in cancer progression.

Interestingly, the research also underscored the role of GM1, a glycolipid molecule that, together with the integrin heterodimers, forms the adhesive interface on the surface of sEVs. GM1 contributes to the binding affinity of vesicles for laminin, enhancing their ability to dock onto target cell membranes. The combined presence of CD151-associated integrins and GM1 is therefore necessary for effective vesicle attachment, which precedes the internalization or signaling events that influence recipient cell behavior.

Another notable aspect of the study pertains to adhesion-related proteins talin and kindlin, which are typically involved in activating integrins in the context of cell adhesion. Despite their association with EVs, talin and kindlin did not activate the integrins on the surface of sEVs in this new molecular context. This indicates a divergent mechanism of integrin activation on EVs compared to that in whole cells, adding a layer of complexity to how vesicles regulate their binding and signaling capabilities.

The implications of these findings extend beyond fundamental cell biology. Given that EVs are being increasingly investigated as biomarkers for disease and as vehicles for drug delivery, understanding how they selectively bind to specific cells opens new avenues for therapeutic intervention. By modulating these adhesion mechanisms — either blocking harmful tumor-derived EVs from seeding metastases or enhancing the targeting of therapeutic EVs to desired tissues — future treatments might achieve greater precision and efficacy.

Professor Suzuki emphasized the translational potential of this research, noting that while EVs have been explored extensively as disease biomarkers, the development of EV-based therapeutics has lagged in part due to incomplete knowledge of their targeting mechanics. The detailed elucidation of integrin heterodimer and GM1-mediated adhesion to laminin advances the field toward rational design of EV-modulating drugs and targeted delivery systems.

The multidisciplinary team, spanning institutions such as Gifu University and the National Cancer Center Research Institute, combined expertise in glycobiology, biophysics, and advanced microscopy to make these discoveries. Their rigorous approach leveraged state-of-the-art single-molecule resolution imaging to parse out subtle molecular interactions that were otherwise undetectable with conventional techniques, exemplifying how technological advances can unlock new biological insights.

The study received extensive support from numerous esteemed Japanese scientific foundations and agencies, reflecting its significance to both basic science and clinical biomedical research. This comprehensive support also underscores the urgency and broad interest in unraveling the complexities of EV biology as it relates to cancer metastasis and more.

As researchers delve deeper into the interplay of extracellular vesicles, integrin complexes, and extracellular matrix proteins like laminin, the prospect of manipulating these pathways offers exciting possibilities. Future strategies might include designing inhibitors that prevent metastatic EVs from docking at remote tissues or engineering EVs that can efficiently target malfunctioning cells to deliver therapeutic molecules, revolutionizing how diseases such as cancer are approached.

In sum, this new research marks a critical step forward in our understanding of the molecular mechanisms governing extracellular vesicle interactions with recipient cells. By delineating the roles of integrin heterodimers, the tetraspanin CD151, and GM1 in selective adhesion to laminin, the study provides a molecular blueprint that could inform the development of next-generation diagnostics and therapeutics targeting cancer metastasis and other pathologies involving intercellular communication.

—

Subject of Research: Cells
Article Title: Extracellular vesicles adhere to cells primarily by interactions of integrins and GM1 with laminin
News Publication Date: 30-Apr-2025
Web References: http://dx.doi.org/10.1083/jcb.202404064
Image Credits: Institute for Glyco-core Research
Keywords: Life sciences, Glycobiology, Membrane biophysics, Single molecule analysis, Cell biology, Adhesion signaling, Integrin signaling, High resolution imaging, Single molecule imaging